Despite the dramatic advances in unraveling the pathophysiology of CAPS, including identification of the gene [26-28], the NLRP3 inflammasome [1], and the introduction of highly effective treatment in the form of IL-1-blocking drugs [29-31], our understanding of this disease is incomplete. The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.